MYRIAD GENETICS, INC. Estimated Litigation Liability, Noncurrent
MYRIAD GENETICS, INC. (MYGN) had Estimated Litigation Liability, Noncurrent of $0 as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:LitigationReserveNoncurrent · last filed 2025-02-28
- 2024-12-31: Estimated Litigation Liability, Noncurrent $0.00.
- 2023-12-31: Estimated Litigation Liability, Noncurrent $24.00M.
| Period end | Estimated Litigation Liability, Noncurrent |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 |
| 2023-12-31 | $24.00M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |